Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
2015; Elsevier BV; Volume: 126; Issue: 7 Linguagem: Inglês
10.1182/blood-2014-12-617522
ISSN1528-0020
AutoresSamantha Jaglowski, Jeffrey A. Jones, Veena Nagar, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Jennifer A. Woyach, Kristie A. Blum, Michael R. Grever, Kelly A. Smucker, Amy S. Ruppert, Nyla A. Heerema, Gerard Lozanski, Mona Stefanos, Brian Munneke, Jamie-Sue West, Jutta K. Neuenburg, Danelle F. James, Nathan C. Hall, Amy J. Johnson, John C. Byrd,
Tópico(s)Immunodeficiency and Autoimmune Disorders
ResumoKey Points Ibrutinib combined with ofatumumab in relapsed CLL had had an ORR of 83% with median time to response of <3 months in all groups. All 3 sequences of administration were acceptably tolerated and active; responses were durable, and median PFS was not yet reached.
Referência(s)